It is of paramount importance that clinical trials with investigational medicinal products containing or consisting of GMOs intended to treat or prevent COVID-19 can be conducted within the Union, that they can begin as soon as possible and that they are not delayed due to the complexity of differing national procedures put in place by Member States in implementation of Directives 2001/18/EC and 2009/41/EC.
Recital 16, Regulation (EU) 2020/1043
In forcesince 15 Jul 2020